IP Library › Granted Patent US 12,497,633
Granted Patent B2
US 12,497,633 · App. 18/964,119 · Granted Dec 16, 2025

Plasmid encoding a TLR9 and Fc fusion protein

Inventor: Bradley G. Thompson (Calgary, CA)
Assignee: Wyvern Pharmaceuticals Inc.
C12N15/86C07K14/48C07K14/62C07K14/705C07K14/70596C12N9/22C07K2319/30C12N2750/14143C12N2800/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,497,633
App. No.
18/964,119
Granted
Dec 16, 2025
Kind
B2
Abstract

Some embodiments of the present disclosure relate to one or more compositions that upregulate the production of one or more sequences of mRNA. The sequences of mRNA may encode for translation of a target biomolecule, thereby causing an increase in bioavailability of the target biomolecule within a subject that is administered the one or more compositions. In some embodiments of the present disclosure, the target biomolecule is a fusion protein with an Fc fragment, such as a toll-like receptor 3-Fc (TLR3-Fc). In some embodiments of the present disclosure, the target biomolecule is toll-like receptor 9-Fc (TLR9-Fc). In some embodiments of the present disclosure, the target biomolecule is deoxyribonuclease I-Fc (DNAse I-Fc). In some embodiments of the present disclosure, the target biomolecule is neural growth factor-Fc (NGF-Fc). In some embodiments of the present disclosure, the target biomolecule is insulin-Fc.

Claims (3)

1 . An isolated plasmid comprising the nucleic acid sequence of SEQ ID NO: 4 encoding a messenger ribonucleic acid (mRNA) encoding a fusion protein comprising a TLR9 protein and an Fc domain.

2 . The isolated plasmid of claim 1 , further comprising one or more pharmaceutically acceptable carriers.

3 . An isolated plasmid comprising the nucleic acid sequence of SEQ ID NO: 9 encoding a messenger ribonucleic acid (mRNA) encoding a fusion protein comprising a TLR9 protein and an Fc domain.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 19, 2025
From: THOMPSON, BRADLEY G.
To: WYVERN PHARMACEUTICALS INC.
Reel/Frame 072059/0930 →
Continuity (2)
Division 18582222 · Feb 20, 2024
Related Publication 20250263742A1 · Aug 21, 2025
References Cited (53)
US 8841416B2 · Ledbetter · 2014 [cited by examiner]
US 11085055B2 · Mallol et al. · 2021 [cited by applicant]
US 11162102B2 · Minshull et al. · 2021 [cited by applicant]
US 11359001B2 · Lancaster · 2022 [cited by applicant]
US 11530423B1 · Thompson · 2022 [cited by applicant]
US 11873505B2 · Thompson · 2024 [cited by applicant]
US 11976104B2 · Wei · 2024 [cited by applicant]
US 12018274B2 · Thompson · 2024 [cited by applicant]
US 12134770B1 · Thompson · 2024 [cited by applicant]
US 12180521B2 · Ledbetter · 2024 [cited by examiner]
US 20030104523A1 · Bauer · 2003 [cited by applicant]
US 20210253664A1 · Wei · 2021 [cited by applicant]
US 20240026377A1 · Thompson · 2024 [cited by applicant]
US 20250002884A1 · Posada · 2025 [cited by examiner]
US 20250011445A1 · Bergmann · 2025 [cited by applicant]
CA 2721333A1 · 2009 [cited by applicant]
CN 114829384 · 2022 [cited by applicant]
KR 100808908B1 · 2008 [cited by applicant]
WO 2004096156A2 · 2004 [cited by applicant]
WO 2020041590A1 · 2020 [cited by applicant]
WO WO2021168413A1 · 2021 [cited by examiner]
WO 2022074236A1 · 2021 [cited by applicant]
WO WO2022178078A1 · 2022 [cited by examiner]
WO 2023051412A1 · 2023 [cited by applicant]
WO 2023088351A1 · 2023 [cited by applicant]
WO WO2024107701A2 · 2024 [cited by examiner]
WO WO2024191937A2 · 2024 [cited by examiner]
Dwyer et al. (J. Biol. Chem. 274:9738-43, 1999) (Year: 1999). [cited by examiner]
Chapter 7 Monomeric Fc-Fusion Proteins Baisong Mei, Susan C. Low, Snejana Krassova, Robert T. Peters, Glenn F. Pierce, Jennifer A. Dumont Book Editor(s):Stefan R. Schmidt First published: Feb. 12, 2013 https://doi.org/1… [cited by examiner]
A rationally engineered DNase1-Fc fusion protein ameliorates autoimmune glomerulonephritis. By: Mouchess, Maria [Reprint Author] Journal of Immunology, (May 1, 2019) vol. 202, No. 1, Suppl. S, pp. 132.4. (Year: 2019). [cited by examiner]
A Rationally Engineered Hyperactive Actin-Resistant DNase1-Fc Fusion Protein Ameliorates Autoimmune Glomerulonephritis. By: Austin, Cary D. Faseb Journal, (Apr. 2019) vol. 33, No. Suppl. 1, pp. 802.10. (Year: 2019). [cited by examiner]
Bottoni et al. “Targeting BTK through microRNA in chronic lymphocytic leukemia.” Blood, The Journal of the American Society of Hematology 128.26 (2016): 3101-3112. [cited by applicant]
O'Brien et al. “Overview of microRNA biogenesis, mechanisms of actions, and circulation.” Frontiers in endocrinology 9 (2018): 402. [cited by applicant]
Gorski et al. “RNA-based recognition and targeting: sowing the seeds of specificity.” Nature Reviews Molecular Cell Biology 18.4 (2017): 215-228. [cited by applicant]
Brutons Tyrosine Kinase Genbank Sequence (2023). [cited by applicant]
Christensen et al. “Recombinant adeno-associated virus-mediated microRNA delivery into the postnatal mouse brain reveals a role for miR-134 in dendritogenesis in vivo.” Frontiers in neural circuits 3 (2010): 848. [cited by applicant]
Bofill-De Ros et al. “Guidelines for the optimal design of miRNA-based shRNAs.” Methods 103 (2016): 157-166. [cited by applicant]
Denzler et al. “Impact of microRNA levels, target-site complementarity, and cooperativity on competing endogenous RNA-regulated gene expression.” Molecular cell 64.3 (2016): 565-579. [cited by applicant]
Van Den Berg et al. “Design of effective primary microRNA mimics with different basal stem conformations.” Molecular Therapy Nucleic Acids 5 (2016). [cited by applicant]
Nature (2010. Gene Expression. Scitable. Available online at Nature.com) <https://www.nature.com/scitable/topicpage/gene-expression-14121669> (2010). [cited by applicant]
GenBank EGF Sequence (2023). [cited by applicant]
Ahmadzadeh et al. “BRAF mutation in hairy cell leukemia.” Oncology reviews 8.2 (2014): 253. [cited by applicant]
Patton et al. “Biogenesis, delivery, and function of extracellular RNA.” Journal of extracellular vesicles 4.1 (2015): 27494. [cited by applicant]
Clark et al. “Detection of BRAF splicing variants in plasma-derived cell-free nucleic acids and extracellular vesicles of melanoma patients failing targeted therapy therapies.” Oncotarget 11.44 (2020): 4016. [cited by applicant]
NCBI search results for SEQ ID No. 5 (2024). [cited by applicant]
NCBI Nucleotide Sequence ALK Lingand, search performed Dec. 26, 2024 (2023). [cited by applicant]
NCBI Nucleotide Sequence ALK Receptor, search performed Dec. 26, 2024 (2023). [cited by applicant]
GenBank EGFR Sequence (2023). [cited by applicant]
GenBank FLT3 Sequence (2024). [cited by applicant]
Wang et al. “Adeno-associated virus vector as a platform for gene therapy delivery.” Nature reviews Drug discovery 18.5 (2019): 358-378. [cited by applicant]
Kondratov et al. “Direct head-to-head evaluation of recombinant adeno-associated viral vectors manufactured in human versus insect cells.” Molecular Therapy 25.12 (2017): 2661-2675. [cited by applicant]
Tritschler et al. “Concepts and limitations for learning developmental trajectories from single cell genomics.” Development 146.12 (2019): dev170506. [cited by applicant]
NCBI Nucleotide Sequence for PARP, search performed Dec. 26, 2024 (2024). [cited by applicant]